Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Oklahoma City, Oklahoma 73104


Purpose:

To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases


Study summary:

Primary Endpoints: 1. Engraftment of donor cells 2. Regimen related toxicities Secondary Endpoints: 1. Disease-free survival 2. Overall survival


Criteria:

Inclusion Criteria: - Performance status 0-2 - Ejection fraction > 30% - AST/ALT and bilirubin not > 4 times normal - Creatinine clearance greater than 70 ml/min. - FEV1 greater than 1.0 and diffusion capacity greater than 40% - Age 18-75 years - Patients must be at high risk for conventional regimen related toxicity - Malignant hematologic disease that would otherwise be considered treatable with ASCT Exclusion Criteria: - Does not meet the above Inclusion criteria


NCT ID:

NCT00582894


Primary Contact:

Principal Investigator
George Selby, MD
University of Oklahoma


Backup Contact:

N/A


Location Contact:

Oklahoma City, Oklahoma 73104
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.